UCB's Keppra XR approved in US
This article was originally published in Scrip
Executive Summary
UCB's Keppra XR, an extended-release formulation of its anti-epileptic Keppra (levetiracetam), has been approved by the US FDAas an add-on to other anti-epileptic treatments in people over 16 years old who have partial onset seizures.